 WILMINGTON, Del.--BUSINESS WIRE--Incyte Nasdaq:INCY today announced that the U.S. Food and Drug Administration FDA has approved Jakafi ruxolitinib for treatment of chronic graft-versus-host disease GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. GVHD is the leading cause of morbidity and mortality in patients following an allogeneic stem cell transplant, yet there historically have been limited treatment options availabl 